Everolimus 2.5mg
| Product Overview | |
| Generic Name | Everolimus 2.5mg |
| Brand Name(s) | Afinitor, Zortress, Certican, Votubia |
| Form | Oral tablets 10 tab pack |
| Strength | 2.5 mg |
| Therapeutic Class | Immunosuppressive/Transplant agent |
| ATC Code | L04AA18 |
| Manufacturing & Regulatory | |
| Manufacturer | Novartis, Multiple Generic mfg's |
| Country | India |
| GMP Compliance | WHO‑GMP |
| DMF/CEP | Type V for generics |
| COFEPRIS | Registered |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 5,000 Tabs/500 Packs |
| Shelf Life | 36 months (sealed) |
| Storage | Store below 30 °C in dry environment; protect from moisture |
| Incoterms | FOB / CIF / DDP |
| Lead Time | 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Provided by manufacturer/distributor |
| SDS | Available (oral tablet – chemical hazard classification) |
| CTD Summary | Full CTD modules 1–5 available from originator or authorized distributors |
Description
Indicated for advanced RCC, hormone-receptor+ breast cancer (with exemestane), progressive NETs, TSC-associated SEGA and angiomyolipoma; also immunosuppression post-transplant
